Simplifying Global Compliance
Part 11 Regulation Revision Not Imminent
Washington Drug Letter
Although the FDA is rebidding its contract for a consultant to help rewrite the Part 11 regulation and related guidance documents, publication of a revision is not expected in the near future.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing